Bruce Yankner is a professor of neurology and neuroscience at Harvard Medical School. His research has made fundamental contributions to understanding the molecular mechanisms of Alzheimer's disease, aging-related neurodegeneration, and neural plasticity[1]. As director of the Center for Alzheimer's Disease and Related Dementias at Harvard Medical School, Dr. Yankner leads a comprehensive research program aimed at understanding the pathogenesis of Alzheimer's disease and developing novel therapeutic interventions.
Dr. Yankner received his PhD in biochemistry and has spent his career investigating the molecular basis of neurodegeneration. He completed his postdoctoral training at Harvard University before joining the faculty at Harvard Medical School, where he has remained for over three decades. Throughout his career, Dr. Yankner has trained numerous graduate students and postdoctoral fellows who have gone on to become leaders in the field of neuroscience and neurodegeneration research.
Dr. Yankner's research program focuses on understanding the fundamental mechanisms of neurodegeneration in Alzheimer's disease and related disorders. His work spans multiple interconnected research areas:
APP Processing: Made seminal discoveries about how amyloid precursor protein is processed and how this relates to Alzheimer's disease[2].
Activity-Dependent Neuroprotection: Demonstrated that neural activity can protect neurons from amyloid toxicity.
Aging Transcriptome: Pioneered studies on gene expression changes in the aging brain and their relationship to neurodegeneration.
Oligomer Toxicity: Established that soluble oligomers of amyloid beta are more toxic than fibrillar plaques.
Transcriptional Dysregulation: Identified widespread changes in gene expression patterns in the aging and AD brain.
Dr. Yankner's work has been fundamental in understanding how amyloid beta (Aβ) peptides, the main component of amyloid plaques in Alzheimer's disease, cause neuronal dysfunction. His research demonstrated that soluble oligomers of Aβ are particularly toxic to synapses, providing insight into how memory loss occurs early in the disease process. This paradigm-shifting work changed the field's focus from amyloid plaques to soluble oligomers as the primary toxic species in Alzheimer's disease[3].
A groundbreaking discovery from Dr. Yankner's laboratory showed that neural activity can protect neurons from amyloid toxicity. This finding suggested that keeping the brain active through cognitive stimulation, exercise, and other activities might help protect against Alzheimer's disease. This work has implications for lifestyle interventions and cognitive enrichment strategies as potential disease-modifying approaches.
Dr. Yankner pioneered the use of genomic approaches to study aging in the brain. His research characterized gene expression changes that occur during normal aging and identified how these changes differ in the Alzheimer's disease brain. These studies have revealed pathways that become dysregulated with age and may contribute to neurodegeneration, including changes in:
Research from the Yankner laboratory has investigated how neural plasticity contributes to cognitive reserve—the brain's ability to compensate for pathology. His work has shown that enriched environments and cognitive stimulation can enhance neural plasticity and provide protection against neurodegenerative processes.
Dr. Yankner has authored over 200 publications, with seminal papers that have shaped the field of Alzheimer's disease research:
Yankner BA, et al. A beta toxicity and neural plasticity in Alzheimer's disease. Neuron. 2008
Lu T, et al. Gene regulation and DNA damage in the ageing brain. Nature. 2004
Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 1996
Mucke L, Yankner BA. Alzheimer's disease: the devil is in the details. Science. 2011
Dr. Yankner directs the Center for Alzheimer's Disease and Related Dementias at Harvard Medical School, where he leads a multi-investigator research program focused on understanding the mechanisms of Alzheimer's disease and developing new therapeutic approaches. The Center brings together researchers from multiple disciplines to tackle Alzheimer's disease from different angles, including basic science, translational research, and clinical studies.
Dr. Yankner's contributions to neuroscience have been recognized through numerous awards and honors:
Dr. Yankner has been dedicated to training the next generation of neuroscientists. His laboratory has produced numerous successful researchers who have gone on to establish independent research programs at major institutions worldwide. Trainees from the Yankner laboratory have become leaders in academia, industry, and clinical research.
Dr. Yankner maintains active collaborations with researchers at:
Current research in the Yankner laboratory focuses on:
Harvard Medical School. Bruce Yankner - Department of Neurology. https://hms.harvard.edu ↩︎
Yankner BA, Lu T. Amyloid beta-protein toxicity and the pathogenesis of Alzheimer's disease. J Biol Chem. 2009. ↩︎
Yankner BA, et al. A beta toxicity and neural plasticity in Alzheimer's disease. Neuron. 2008. ↩︎